Veronica Sanchez-Corrales

Albacete, CM 02002, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.

Journal: International journal of molecular sciences

Published: November 18, 2020

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.

Journal: Cancer letters

Published: April 09, 2020

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: February 20, 2020

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.

Journal: Journal of cellular and molecular medicine

Published: October 28, 2018

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Journal: Oncotarget

Published: August 02, 2017

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Journal: Scientific reports

Published: June 12, 2017

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Journal: Molecular cancer therapeutics

Published: March 11, 2017

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Journal: Oncotarget

Published: October 19, 2016

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Journal: Oncotarget

Published: June 20, 2016

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Journal: Oncotarget

Published: May 23, 2016

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Journal: Molecular cancer therapeutics

Published: January 20, 2016

Circulating DNA and Survival in Solid Tumors.

Circulating DNA and Survival in Solid Tumors.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: August 24, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026